Clinical Care Options Oncology - Leukemia via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Care Options Oncology - Leukemia' source. Sun, 14 Mar 2010 14:25:13 +0100 Chronic Myelogenous Leukemia http://www.medworm.com/index.php?rid=3324540&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCML.aspx Learning Module - Join Brian Druker, MD; Elias Jabbour, MD; Neil P. Shah, MD, PhD; and Moshe Talpaz, MD, as they review the clinical implications of research on chronic myelogenous leukemia presented at the 2009 Hematology meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3324540 Tue, 02 Mar 2010 12:00:00 +0100 3324540 Acute Leukemias http://www.medworm.com/index.php?rid=3313069&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FALL_and_AML.aspx Learning Module - Dan Douer, MD; Hagop M. Kantarjian, MD; Farhad Ravandi, MD; and Martin S. Tallman, MD, discuss the clinical implications of study data presented at the 2009 Hematology meeting on the treatment of AML and ALL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3313069 Fri, 26 Feb 2010 12:00:00 +0100 3313069 Slideset: The Role of Allogeneic Hematopoietic Cell Transplantation in AML http://www.medworm.com/index.php?rid=3281339&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FAppelbaum.aspx CCO Slideset - Download a slideset in which Frederick Appelbaum, MD, explores the changes improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3281339 Wed, 17 Feb 2010 10:56:47 +0100 3281339 Slideset: Advances in AML/MDS: The Role of Multicenter Clinical Trials http://www.medworm.com/index.php?rid=3277528&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FConfer.aspx CCO Slideset - Download a slideset in which Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277528 Fri, 12 Feb 2010 12:00:00 +0100 3277528 Slideset: Incorporating Molecular Data into Risk Stratification for AML http://www.medworm.com/index.php?rid=3277527&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FDevine.aspx CCO Slideset - Download a slideset in which Steven Devine, MD, provides up-to-date information on risk stratification in patients with AML, and discusses how this affects treatment choices. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277527 Fri, 12 Feb 2010 12:00:00 +0100 3277527 Advances in AML/MDS: The Role of Multicenter Clinical Trials http://www.medworm.com/index.php?rid=3277526&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FAML_MDS_Transplantation_Trials.aspx CCO Virtual Presentation - Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS, including studies available through the Blood and Marrow Transplant Clinical Trials Network. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277526 Fri, 12 Feb 2010 12:00:00 +0100 3277526 Options for High Risk AML and MDS http://www.medworm.com/index.php?rid=3360854&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FOptions_for_High-Risk_AML_and_MDS.aspx CCO Virtual Presentation - Daniel Weisdorf, MD, provides an overview of the considerations for allogeneic transplantation in patients with high-risk AML or those with MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3360854 Thu, 11 Feb 2010 12:00:00 +0100 3360854 Options for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes http://www.medworm.com/index.php?rid=3277529&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FOptions_for_High-Risk_AML_and_MDS.aspx CCO Virtual Presentation - Daniel Weisdorf, MD, provides an overview of the considerations for allogeneic transplantation in patients with high-risk AML or those with MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277529 Thu, 11 Feb 2010 12:00:00 +0100 3277529 The Role of Allogeneic Hematopoietic Cell Transplantation in AML http://www.medworm.com/index.php?rid=3277530&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FAllogeneic_HCT_in_AML.aspx CCO Virtual Presentation - Frederick R. Appelbaum, MD, explores the changes that have improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277530 Wed, 10 Feb 2010 11:42:40 +0100 3277530 The Role of Allogeneic Hematopoietic Cell Transplantation in AML http://www.medworm.com/index.php?rid=3260647&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FAllogeneic_HCT_in_AML.aspx CCO Virtual Presentation - Frederick R. Appelbaum, MD, explores the changes improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3260647 Wed, 10 Feb 2010 11:42:40 +0100 3260647 Slideset: The Role of Allogeneic Hematopoietic Cell Transplantation in AML http://www.medworm.com/index.php?rid=3260648&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FAppelbaum.aspx CCO Slideset - Download a slideset in which Frederick Appelbaum, MD, explores the changes improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3260648 Wed, 10 Feb 2010 11:41:13 +0100 3260648 Slideset: Options for High Risk AML and MDS http://www.medworm.com/index.php?rid=3277531&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FWeisdorf.aspx CCO Slideset - Download a slideset in which Daniel Weisdorf, MD, provides an overview of considerations for allogeneic transplantation in patients with high-risk AML or those with MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277531 Wed, 10 Feb 2010 00:00:00 +0100 3277531 Advances in AML/MDS: The Role of Multicenter Clinical Trials http://www.medworm.com/index.php?rid=3256539&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FAML_MDS_Transplantation_Trials.aspx CCO Virtual Presentation - Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials, including studies available through the Blood and Marrow Transplant Clinical Trials Network, in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3256539 Tue, 09 Feb 2010 12:00:00 +0100 3256539 Slideset: Advances in AML/MDS: The Role of Multicenter Clinical Trials http://www.medworm.com/index.php?rid=3260650&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FConfer.aspx CCO Slideset - Download a slideset in which Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3260650 Tue, 09 Feb 2010 00:00:00 +0100 3260650 Incorporating Molecular Data Into Risk Stratification for AML http://www.medworm.com/index.php?rid=3277532&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FAML_Risk_Stratification.aspx CCO Virtual Presentation - Steven M. Devine, MD, provides up-to-date information on risk stratification in patients with AML and discusses how data on karyotyping, molecular markers, and age affect treatment choices. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277532 Thu, 04 Feb 2010 16:03:32 +0100 3277532 Slideset: Incorporating Molecular Data into Risk Stratification for AML http://www.medworm.com/index.php?rid=3241353&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FDevine.aspx CCO Slideset - Download a slideset in which Steven Devine, MD, provides up-to-date information on risk stratification in patients with AML, and discusses how this affects treatment choices. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3241353 Thu, 04 Feb 2010 00:00:00 +0100 3241353 Acute Leukemias and Myelodysplastic Syndromes http://www.medworm.com/index.php?rid=3161163&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FCCO%2520Slidesets%2FAcute_Leukemias.aspx CCO Slideset - Hagop Kantarjian MD, provides a slideset summary of the most notable studies in ALL, AML, and MDS presented at the 2009 Hematology Annual Meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3161163 Mon, 11 Jan 2010 00:00:00 +0100 3161163 No Improvement in Activity With Addition of Lestaurtinib to Chemotherapy in FLT3 Mutant AML Patients in First Relapse http://www.medworm.com/index.php?rid=3080734&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F788.aspx Capsule Summary - Results of a phase II trial of FLT3 inhibitor lestaurtinib in combination with chemotherapy in AML patients in first relapse show no additional clinical activity and identified unfavorable pharmacokinetics. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3080734 Fri, 11 Dec 2009 16:13:55 +0100 3080734 AML SWOG S0106: Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Fails to Improve Response in AML Patients http://www.medworm.com/index.php?rid=3080735&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F790.aspx Capsule Summary - Although there was no benefit to adding gemtuzumab ozogamicin to induction therapy, consolidation with this agent was associated with a potential relapse-free survival benefit among AML patients with favorable cytogenetics. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3080735 Fri, 11 Dec 2009 14:19:59 +0100 3080735 High Response Rates With High-Dose Lenalidomide Induction Therapy in AML Patients 60 Years of Age or Older http://www.medworm.com/index.php?rid=3080736&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F842.aspx Capsule Summary - CRs to high-dose lenalidomide induction persisted for > 6 months in 40% of responding patients in this single-arm phase II trial. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3080736 Fri, 11 Dec 2009 08:44:58 +0100 3080736 Complete Molecular Remission Durable in Some CML Patients Following Imatinib Discontinuation http://www.medworm.com/index.php?rid=3077151&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F859.aspx Capsule Summary - One-year results from the prospective, multicenter STIM study show the likelihood of sustained CMR 12 months following imatinib discontinuation was higher among male vs female patients and among patients with low vs intermediate or high Sokal scores. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077151 Thu, 10 Dec 2009 17:49:13 +0100 3077151 High-Dose Imatinib Associated With Superior 12-Month MMR vs Standard-Dose Imatinib +/- Interferon in Previously Untreated Chronic-Phase Ph-Positive CML http://www.medworm.com/index.php?rid=3077152&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F339.aspx Capsule Summary - MMR-specific results of the randomized German CML Study IV showed a higher rate of MMR and more rapid response, but not improved survival, for imatinib 800 mg vs 400 mg with or without interferon in patients with newly diagnosed Ph-positive CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077152 Thu, 10 Dec 2009 13:28:14 +0100 3077152 Rapid, High Rate of Complete Cytogenetic Response Observed With First-line Nilotinib in Patients With Chronic-Phase Ph-Positive CML http://www.medworm.com/index.php?rid=3077153&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F341.aspx Capsule Summary - Results of a phase II single-arm study of nilotinib as first-line treatment of patients with chronic-phase Ph-positive CML show rapid efficacy with acceptable toxicities. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077153 Thu, 10 Dec 2009 13:09:29 +0100 3077153 Lenalidomide 5 mg and 10 mg Both Improve RBC Transfusion Independence and Cytogenetic Response Compared With Placebo in Low- and Intermediate-1–Risk MDS With Chromosome 5q Deletion http://www.medworm.com/index.php?rid=3077155&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F944.aspx Capsule Summary - There was a trend toward improved outcomes with the 10-mg dose, with similar safety and no evidence of increased AML progression vs an untreated population, in this phase III randomized trial. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077155 Thu, 10 Dec 2009 12:00:00 +0100 3077155 Omacetaxine Safe, Active in CML Patients With T315I Mutation and in Those Who Failed Multiple Previous TKI Therapies http://www.medworm.com/index.php?rid=3077154&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F644.aspx Capsule Summary - In 2 single-arm multicenter phase II/III trials of omacetaxine, myelosuppression was the most frequent grade 3/4 toxicity and ≥ grade 3 nonhematologic adverse events were infrequent. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077154 Thu, 10 Dec 2009 12:00:00 +0100 3077154 Alemtuzumab Plus Fludarabine Improves PFS Compared With Fludarabine Monotherapy in Relapsed/Refractory CLL http://www.medworm.com/index.php?rid=3073110&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCLL%2FCapsules%2F537.aspx Capsule Summary - Significantly higher ORR and CR rate seen with fludarabine plus alemtuzumab compared with fludarabine alone. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073110 Wed, 09 Dec 2009 20:06:11 +0100 3073110 Rapid, High Rate of Complete Cytogenetic Response With First-line Dasatinib in Patients With Chronic-Phase CML http://www.medworm.com/index.php?rid=3073111&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F338.aspx Capsule Summary - Randomized phase II study results show high response rates with both once-daily and twice-daily dasatinib dosing for first-line treatment of CML, although dose reductions were more frequent with twice-daily dosing. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073111 Wed, 09 Dec 2009 19:38:32 +0100 3073111 Interim Results Suggest Once-Daily, Low-Dose Decitabine Safe, Active in Patients With Lower-Risk MDS http://www.medworm.com/index.php?rid=3073112&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F119.aspx Capsule Summary - In this phase II study, response rates to decitabine therapy were higher with daily dosing vs weekly low-intensity dosing. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073112 Wed, 09 Dec 2009 15:15:22 +0100 3073112 2-Year TOPS Results Show Comparable Results for Imatinib at 400 mg and 800 mg and Highlight Importance of Minimizing Dose Interruptions http://www.medworm.com/index.php?rid=3073113&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F337.aspx Capsule Summary - Lower rates of MMR and CCyR were observed in patients who had ≥ 2 dose interruptions. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073113 Wed, 09 Dec 2009 13:26:49 +0100 3073113 AC220, a Second-Generation Receptor Tyrosine Kinase Inhibitor, Safe and Effective in Relapsed and Refractory AML http://www.medworm.com/index.php?rid=3073114&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F636.aspx Capsule Summary - In the first in-human study, AC220 responses higher in AML patients harboring FLT3 internal tandem duplications. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073114 Wed, 09 Dec 2009 12:00:00 +0100 3073114 MRC-AML15: Findings Show OS in AML Similar With Multiple Different Induction and Consolidation Therapies http://www.medworm.com/index.php?rid=3073115&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F484.aspx Capsule Summary - In patients with adverse prognostic indicators, the 5-year OS rate is significantly higher with amsacrine, Ara-C, etoposide followed by mitoxantrone and Ara-C. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073115 Wed, 09 Dec 2009 10:58:44 +0100 3073115 Alemtuzumab Produces Durable Responses in MDS Patients Who Have Favorable Predictors of Response to Immunosuppressive Therapy (IST) http://www.medworm.com/index.php?rid=3073116&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F116.aspx Capsule Summary - In this single-arm phase II pilot study, 75% of patients with transfusion-dependent anemia became transfusion independent following alemtuzumab therapy. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073116 Wed, 09 Dec 2009 09:13:08 +0100 3073116 HOVON-70 Study: Dose-Intensified Chemotherapy Regimens Safe and Efficacious in Adult ALL Patients http://www.medworm.com/index.php?rid=3068761&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F323.aspx Capsule Summary - In this nonrandomized phase II study, dose-intensified chemotherapy was associated with improved outcomes in adult ALL patients. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3068761 Tue, 08 Dec 2009 14:58:03 +0100 3068761 Oral Clofarabine Yields Responses in Patients With Higher-Risk MDS http://www.medworm.com/index.php?rid=3064731&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F118.aspx Capsule Summary - In this phase II study of single-agent clofarabine, transaminase elevations and acute renal failure were the most common grade 3/4 adverse events. Further research is needed to define the optimal dosing schedule. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3064731 Mon, 07 Dec 2009 12:13:00 +0100 3064731 Sapacitabine, a Novel Oral Nucleoside Analogue, Safe and Active in Elderly Patients With Untreated AML or AML in First Relapse http://www.medworm.com/index.php?rid=3062194&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F1061.aspx Capsule Summary - Sapacitabine safe and active in elderly AML patients (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3062194 Sun, 06 Dec 2009 17:34:58 +0100 3062194 Nilotinib More Effective Than Imatinib in Achieving Molecular and Cytogenic Responses in Patients With Newly Diagnosed Chronic-Phase Ph-Positive CML http://www.medworm.com/index.php?rid=3080737&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2FLBA-1.aspx Capsule Summary - According to the findings of the ENESTnd trial of 2 schedules of nilotinib (300 mg or 400 mg twice daily) vs imatinib 400 mg once daily, nilotinib more effective than imatinib at inducing MMR and CCyR in newly diagnosed patients with chronic-phase Ph-positive CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3080737 Sat, 05 Dec 2009 00:00:00 +0100 3080737 Omacetaxine Active With Minimal Toxicity in T315I-Positive CML Patients Who Failed Imatinib http://www.medworm.com/index.php?rid=2460275&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7008.aspx Capsule Summary - Omacetaxine resulted in durable hematologic and cytogenetic responses with an acceptable safety profile in patients with T315I-positive chronic myeloid leukemia following failure of imatinib therapy. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2460275 Wed, 03 Jun 2009 11:18:54 +0100 2460275 High-Dose Daunorubicin Induction Improves OS in Acute Myeloid Leukemia http://www.medworm.com/index.php?rid=2449673&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7003.aspx Capsule Summary - Increasing the dose of daunorubicin prior to transplantation provides a survival advantage without increased toxicity in younger patients with de novo AML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2449673 Tue, 02 Jun 2009 17:58:35 +0100 2449673 Galectin-3 Inhibitor GCS-100 Shows Single-Agent Activity in Elderly Patients With Relapsed Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=2449674&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7006.aspx Capsule Summary - GCS-100, a galectin-3 antagonist, shows antitumor and apoptotic activity and has acceptable toxicity in elderly patients with relapsed CLL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2449674 Tue, 02 Jun 2009 17:02:59 +0100 2449674 Single-Agent Ofatumumab Produces Clinical Benefit in Patients With Double-Refractory or Bulky Fludarabine-Refractory CLL http://www.medworm.com/index.php?rid=2449675&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7043.aspx Capsule Summary - Single-agent ofatumumab therapy provided a clinically significant response rates and a survival benefit among responders, according to investigators. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2449675 Sun, 31 May 2009 16:41:49 +0100 2449675 Allogeneic Transplantation for Ph+ Acute Lymphoblastic Leukemia http://www.medworm.com/index.php?rid=2384175&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%25202009%2FInteractive%2520Virtual%2520Presentations%2FIVP%2C-c-%2C%2520Ph%2B%2520ALL.aspx CCO Virtual Presentation - Jacob M. Rowe, MD, FACP, explores current thinking regarding treatment strategies for adults with acute lymphoblastic leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2384175 Thu, 30 Apr 2009 12:00:00 +0100 2384175 Allogeneic Transplantation for Ph+ Acute Lymphoblastic Leukemia http://www.medworm.com/index.php?rid=2384176&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%25202009%2FInteractive%2520Virtual%2520Presentations%2FAllogeneic%2520Transplantation.aspx CCO Slideset - Download a slide presentation by Jacob M. Rowe, MD, FACP, focusing on allogeneic transplantation in patients with Philadelphia chromosome–positive ALL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2384176 Thu, 30 Apr 2009 00:00:00 +0100 2384176 ALL in Special Populations: Adolescents/Young Adults and Older Adults http://www.medworm.com/index.php?rid=2739258&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%25202009%2FInteractive%2520Virtual%2520Presentations%2FAdult%2520ALL%2520Slides.aspx CCO Slideset - Download a presentation by Adele K. Fielding, MB BS, PhD, FRCP, FRCPath, in which she reviews treatment strategies in 2 special patient populations affected by ALL: young adults and the elderly. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2739258 Thu, 23 Apr 2009 12:42:31 +0100 2739258 ALL in Special Populations: Adolescents/Young Adults and Older Adults http://www.medworm.com/index.php?rid=2334164&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%25202009%2FInteractive%2520Virtual%2520Presentations%2FIVP%2C-c-%2C%2520Adult%2520ALL.aspx CCO Virtual Presentation - Adele K. Fielding, MB BS, PhD, FRCP, FRCPath, reviews strategies to improve treatment outcomes in 2 special patient populations affected by ALL: young adults and the elderly. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2334164 Mon, 13 Apr 2009 00:00:00 +0100 2334164 Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=2309661&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FConference%2520Sub%2520Programs%2FCML%2520Slideset%2FCCO%2520Slideset%2FSlideset%2520Module.aspx Learning Module - Download a slideset created by Charles L. Sawyers, MD, and Moshe Talpaz, MD, that reviews the latest data on chronic myeloid leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia, and the clinical implications. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309661 Wed, 11 Mar 2009 00:00:00 +0100 2309661 Chronic Lymphocytic Leukemia/Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=2309662&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCLL%2520and%2520CML.aspx Learning Module - Expert faculty members discuss the most important data in CLL and CML presented in San Francisco, California. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309662 Fri, 06 Mar 2009 14:28:11 +0100 2309662 Acute Leukemias/Myelodysplastic Syndromes http://www.medworm.com/index.php?rid=2309663&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FVirtual%2520Presentation%2520Programs%2FAcute%2520leukemias%2520and%2520MDS%2FAcute%2520Leukemias%2520and%2520Myelodysplastic%2520Syndromes.aspx CCO Expert Recap - Hagop M. Kantarjian, MD, provides an up-to-date analysis of the most clinically relevant new data on acute leukemias and myelodysplastic syndromes presented at the 2008 Annual Meeting of the American Society of Hematology. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309663 Thu, 26 Feb 2009 09:04:03 +0100 2309663 Acute Leukemias/Myelodysplastic Syndromes http://www.medworm.com/index.php?rid=2309664&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FAcute%2520Leukemias%2520and%2520MDS.aspx Learning Module - Read a discussion between Hagop M. Kantarjian, MD; Alan F. List, MD; and Martin S. Tallman, MD, about the latest studies on acute leukemias and MDS presented at the ASH 2008 meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309664 Thu, 05 Feb 2009 10:00:50 +0100 2309664 Acute Leukemias and Myelodysplastic Syndromes http://www.medworm.com/index.php?rid=2309665&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FVirtual%2520Presentation%2520Programs%2FAcute%2520leukemias%2520and%2520MDS%2FAL%2520and%2520MDS.aspx CCO Slideset - Download slides on the latest data on acute leukemias and myelodysplastic syndromes from the 2008 Hematology meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309665 Wed, 14 Jan 2009 00:00:00 +0100 2309665 Hematologic Malignancies http://www.medworm.com/index.php?rid=2632168&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FVirtual%2520Presentation%2520Programs%2FHematologic%2520Malignancies%2520ER%2FHematologic_Malignancies.aspx CCO Expert Recap - Edward Stadtmauer, MD, reviews the most important studies presented at the 2009 Clinical Oncology meeting in the settings of multiple myeloma, lymphomas, and leukemias. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2632168 Wed, 07 Jan 2009 00:00:00 +0100 2632168 Combination of Sorafenib, Idarubicin, Cytarabine Effective in Patients Younger Than 65 Years of Age With Previously Untreated AML http://www.medworm.com/index.php?rid=2309666&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F768.aspx Capsule Summary - Phase I/II study show sorafenib plus idarubicin and cytarabine effective and well tolerated as frontline therapy of younger patients with AML, and that sorafenib may have in vivo inhibitory activity toward ERK and FLT3 signaling. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309666 Sat, 13 Dec 2008 18:52:58 +0100 2309666 Iron Overload and Transfusion-Dependence Independently Prognostic of OS and Leukemia-Free Survival in MDS http://www.medworm.com/index.php?rid=2309667&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F640.aspx Capsule Summary - Retrospective analysis of patients with primary MDS shows development of iron overload and RBC transfusion dependency both independent prognostic factors of OS and leukemia-free survival. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309667 Sat, 13 Dec 2008 14:40:32 +0100 2309667 Nilotinib Induces Response in Previously Untreated Ph+ Early Chronic-Phase CML http://www.medworm.com/index.php?rid=2309668&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCapsules%2F446.aspx Capsule Summary - Nilotinib induces rapid complete cytogenetic responses and has favorable toxicity profile in early chronic-phase CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309668 Sat, 13 Dec 2008 13:22:02 +0100 2309668 STIM Study Shows CML Complete Molecular Remission Possible to Maintain Following Imatinib Discontinuation http://www.medworm.com/index.php?rid=2309669&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCapsules%2F187.aspx Capsule Summary - The probability of sustaining complete molecular remission through Month 9 was intriguingly higher among patients who received previous treatment with interferon, vs those who did not; however, the difference in this small study was not statistically significant. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309669 Sat, 13 Dec 2008 13:15:26 +0100 2309669 Imatinib 800 mg/day Achieves Earlier Major Molecular Response vs Imatinib 400 mg/day in Newly Diagnosed Chronic-Phase CML http://www.medworm.com/index.php?rid=2309670&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCapsules%2F335.aspx Capsule Summary - Both imatinib doses were generally well tolerated with fewer than 10% of patients discontinuing treatment in each arm. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309670 Sat, 13 Dec 2008 12:57:45 +0100 2309670 Cladribine, but not Fludarabine, Addition to Daunorubicin-Cytarabine Regimen Improved Survival Adults With Previously Untreated AML http://www.medworm.com/index.php?rid=2309671&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F133.aspx Capsule Summary - Addition of cladribine or fludarabine to standard daunorubicin-cytarabine induction therapy in a phase III study in patients with AML showed survival benefit of cladribine, but not fludarabine. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309671 Sat, 13 Dec 2008 00:00:00 +0100 2309671 Pomalidomide Active, Well Tolerated in Anemic Patients With Myelofibrosis http://www.medworm.com/index.php?rid=2309672&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F663.aspx Capsule Summary - Multicenter phase II trial of pomalidomide with or without prednisone in anemic patients with myelofibrosis showed increase in hemoglobin levels in 25% of patients (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309672 Fri, 12 Dec 2008 12:42:54 +0100 2309672 Cytogenetic Response to Dasatinib Predictive for Progression-Free Survival in Imatinib-Resistant/Intolerant CML Patients http://www.medworm.com/index.php?rid=2309673&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCapsules%2F450.aspx Capsule Summary - Rapid, durable cytogenetic responses to dasatinib were predictive of PFS in chronic-phase CML patients who were resistant to or intolerant of imatinib therapy. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309673 Fri, 12 Dec 2008 12:11:56 +0100 2309673 Addition of Rituximab to Fludarabine/Cyclophosphamide Improves PFS in Relapsed/Refractory CLL Patients http://www.medworm.com/index.php?rid=2309674&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCapsules%2FLBA1.aspx Capsule Summary - Rituximab plus fludarabine/cyclophosphamide produces significantly longer PFS vs fludarabine/cyclophosphamide alone in patients with relapsed/refractory CLL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309674 Fri, 12 Dec 2008 12:00:00 +0100 2309674 European Proposal for Standard Chemotherapy of Elderly Patients With Previously Untreated ALL Effective and Well Tolerated http://www.medworm.com/index.php?rid=2309675&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F304.aspx Capsule Summary - Induction with a standard chemotherapy backbone designed for elderly patients was associated with CR in 81% of previously untreated ALL patients older than 55 years of age. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309675 Fri, 12 Dec 2008 10:13:14 +0100 2309675 Romiplostim Well Tolerated in Patients Receiving Azacitidine for Low- or Intermediate-Risk MDS http://www.medworm.com/index.php?rid=2309676&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F224.aspx Capsule Summary - Romiplostim was associated with higher platelet counts over time and decreased incidence of thrombocytopenia and platelet transfusions relative to placebo, but the differences were not significant in this small population. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309676 Fri, 12 Dec 2008 09:38:39 +0100 2309676 Single-Agent Clofarabine Active and Well Tolerated in Older Adults With Untreated Acute Myelogenous Leukemia Accompanied by Unfavorable Risk Factors http://www.medworm.com/index.php?rid=2309678&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F558.aspx Capsule Summary - Phase II trial of clofarabine in patients 60 years of age or older showed this approach safe and effective in this patient population that has poor prognostic indicators. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309678 Fri, 12 Dec 2008 00:00:00 +0100 2309678 Once-Daily Decitabine 5-Day Regimen Active and Well Tolerated in Previously Untreated Elderly Patients With Acute Myeloid Leukemia http://www.medworm.com/index.php?rid=2309677&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F560.aspx Capsule Summary - Responses were observed in all patient subgroups, including those with poor cytogenetic risk. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309677 Fri, 12 Dec 2008 00:00:00 +0100 2309677 Ongoing Azacitidine Treatment May Maximize Benefit in Patients With MDS http://www.medworm.com/index.php?rid=2309679&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F227.aspx Capsule Summary - Continued azacitidine treatment following the achievement of a first response in higher-risk MDS patients resulted in an increased level of response in the AZA-001 phase III study. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309679 Thu, 11 Dec 2008 20:09:06 +0100 2309679 In European MDS/AML Study, Maintenance Azacitidine Treatment Feasible but Without “Clear Effect” http://www.medworm.com/index.php?rid=2309680&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F223.aspx Capsule Summary - Methylation of CDH and of all genes was associated with poorer survival and lower CR rate. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309680 Thu, 11 Dec 2008 20:02:45 +0100 2309680 Frontline Subcutaneous Low-Dose Alemtuzumab Safe and Effective in Elderly CLL Patients With 17p Deletion http://www.medworm.com/index.php?rid=1954186&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FHematology%2FCapsules%2F7048.aspx Subcutaneous low-dose alemtuzumab is as effective as frontline IV administration in elderly CLL patients with the 17p chromosomal deletion (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1954186 Thu, 13 Nov 2008 08:14:18 +0100 1954186 Addition of Imatinib to Hyper-CVAD May Improve Outcomes in Patients With Ph-Positive Acute Lymphoblastic Leukemia http://www.medworm.com/index.php?rid=1916958&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FHematology%2FCapsules%2F7019.aspx Imatinib added to hyper-CVAD resulted in a high rate of durable remissions in patients with de novo or minimally treated Ph-positive ALL (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1916958 Thu, 30 Oct 2008 07:36:29 +0100 1916958 Novel JAK Inhibitor INCB018424 Active in Patients With Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis http://www.medworm.com/index.php?rid=1898888&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FHematology%2FCapsules%2F7004.aspx Novel oral JAK inhibitor INCB018424 associated with substantial durable reductions in spleen size in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1898888 Fri, 24 Oct 2008 07:59:06 +0100 1898888 Virtual Presentation: Non-Hodgkin’s Lymphoma http://www.medworm.com/index.php?rid=1888793&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHeme%2520Highlights%25202008%2FVirtual%2520Presentations%2FNon-Hodgkin%25e2%2580%2599s%2520Lymphoma%2520VP.aspx Sandra J. Horning, MD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with non-Hodgkin’s lymphoma. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1888793 Mon, 20 Oct 2008 07:36:20 +0100 1888793 New TKI Bosutinib Active in Chronic-Phase CML Resistant to Other TKIs http://www.medworm.com/index.php?rid=1814328&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202008%2FTracks%2FHematology%2FCapsules%2F7001.aspx Novel TKI bosutinib active in patients with chronic-phase CML with imatinib intolerance or resistance, or resistance to second-generation TKIs (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1814328 Tue, 23 Sep 2008 07:55:51 +0100 1814328 Virtual Presentation: Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=1804950&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHeme%2520Highlights%25202008%2FVirtual%2520Presentations%2FCML%2520VP.aspx Neil Shah, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with chronic myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1804950 Fri, 19 Sep 2008 07:44:11 +0100 1804950 Virtual Presentation: Non-Hodgkins Lymphoma http://www.medworm.com/index.php?rid=1732327&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHeme%2520Highlights%25202008%2FVirtual%2520Presentations%2FNon-Hodgkin%25e2%2580%2599s%2520Lymphoma%2520VP.aspx Sandra J. Horning, MD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with non-Hodgkins lymphoma. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1732327 Wed, 27 Aug 2008 06:54:41 +0100 1732327 Virtual Presentation: Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=1699051&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHeme%2520Highlights%25202008%2FVirtual%2520Presentations%2FCLL%2520VP.aspx Michael J. Keating, MB BS, discusses results presented at the 2007 hematology meeting regarding chronic lymphocytic leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1699051 Wed, 13 Aug 2008 06:47:23 +0100 1699051 Virtual Presentation: Myelodysplastic Syndrome http://www.medworm.com/index.php?rid=1654301&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHeme%2520Highlights%25202008%2FVirtual%2520Presentations%2FMDS%2520VP.aspx Allen S. Yang, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with myelodysplastic syndrome. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1654301 Sat, 26 Jul 2008 06:40:31 +0100 1654301 Virtual Presentation: Acute Leukemias http://www.medworm.com/index.php?rid=1540394&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHeme%2520Highlights%25202008%2FVirtual%2520Presentations%2FAcute%2520Leukemias%2520VP.aspx Farhad Ravandi, MD, discusses results presented at the 2007 hematology meeting regarding acute leukemias. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1540394 Wed, 25 Jun 2008 20:09:50 +0100 1540394 Virtual Presentation: Multiple Myeloma http://www.medworm.com/index.php?rid=1476456&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHeme%2520Highlights%25202008%2FVirtual%2520Presentations%2FMultiple%2520Myeloma%2520VP.aspx Amitabha Mazumder, MD, discusses new data in multiple myeloma presented at the 2007 hematology meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1476456 Fri, 30 May 2008 14:04:03 +0100 1476456 Management of a 69-Year-Old Patient With Deletion 5q Myelodysplastic Syndrome http://www.medworm.com/index.php?rid=1435403&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FMDS%2520Treatment%2FInteractive%2520Case%2520Challenges%2FCase%25202.aspx Alan F. List, MD, reviews treatment options for a patient with del(5q) MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1435403 Mon, 12 May 2008 22:55:10 +0100 1435403 Clinical Management of a 69-Year-Old Man With Intermediate-1-Risk Myelodysplastic Syndrome http://www.medworm.com/index.php?rid=1395594&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FMDS%2520Treatment%2FInteractive%2520Case%2520Challenges%2FCase%25201.aspx In this Interactive Case Challenge, Azra Raza, MD, and Naomi Galili, PhD, discuss treatment options for a patient with intermediate-risk myelodysplastic syndrome and monosomy of chromosome 7. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1395594 Thu, 24 Apr 2008 19:16:36 +0100 1395594 Slideset Module: Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=1387790&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007.aspx Download a slideset created by Charles L. Sawyers, MD, and Moshe Talpaz, MD, that reviews the latest data on chronic myeloid leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia, and the clinical implications. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1387790 Tue, 22 Apr 2008 07:02:52 +0100 1387790 Expert Analysis: Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=1367295&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FExpert%2520Analysis.aspx Moshe Talpaz, MD; Brian Druker, MD; Charles L. Sawyers, MD; and Allen Yang, MD, PhD, review clinical data on chronic myeloid leukemia presented at the 2007 hematology meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1367295 Sat, 12 Apr 2008 07:06:11 +0100 1367295 Expert Recap: Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=1364284&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FVirtual%2520Presentation%2520Programs%2FCML%2FCML%2520ER.aspx Watch and listen as Moshe Talpaz, MD, reviews the latest data on chronic myeloid leukemia treatment presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1364284 Fri, 11 Apr 2008 06:54:17 +0100 1364284 Expert Recap: Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=1346628&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FVirtual%2520Presentation%2520Programs%2FCLL%2FCLL.aspx In this Expert Recap, Michael J. Keating, MB BS, reviews the most up-to-date data on chronic lymphocytic leukemia presented at the 2007 annual hematology meeting in Atlanta, Georgia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1346628 Thu, 03 Apr 2008 10:20:50 +0100 1346628 Expert Analysis: Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=1329661&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FExpert%2520Analysis.aspx John C. Byrd, MD, Michael J. Keating, MB BS, and Kanti Rai, MD, discuss the latest clinical data on treatment of chronic lymphocytic leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Roy A. Beveridge, MD. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1329661 Thu, 27 Mar 2008 08:25:12 +0100 1329661 Expert Analysis: Acute Leukemias http://www.medworm.com/index.php?rid=1312084&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FExpert%2520Analysis.aspx Hagop M. Kantarjian, MD; Dan Douer, MD; and Stephen J. Forman, MD, discuss the latest clinical data on treatment of acute leukemias presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Mark Kirschbaum, MD. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1312084 Wed, 19 Mar 2008 07:10:51 +0100 1312084 Expert Analysis: Myelodysplastic Syndromes http://www.medworm.com/index.php?rid=1302416&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FMDS%2FExpert%2520Analysis.aspx Read a discussion among Alan F. List, MD; Lewis R. Silverman, MD; and Azra Raza, MD, and moderated by Allan S. Yang, MD, PhD, on the key studies presented at ASH 2007 regarding treatment and pathogenesis of myelodysplastic syndromes. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1302416 Fri, 14 Mar 2008 19:03:39 +0100 1302416 Pretransplant Imatinib During First Chronic Phase Associated With Improved Survival in CML http://www.medworm.com/index.php?rid=1299388&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F738.aspx Patients with CML in first chronic phase treated with imatinib prior to HSCT have improved survival vs patients who do not receive imatinib (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1299388 Thu, 13 Mar 2008 19:07:53 +0100 1299388 Bosutinib Active and Well Tolerated in Heavily Pretreated Patients With Chronic-Phase CML http://www.medworm.com/index.php?rid=1284138&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F733.aspx Novel dual TKI of ABL and Src, bosutinib, induces responses in patients with treatment-experienced chronic-phase CML after previous TKI treatment failure (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1284138 Fri, 07 Mar 2008 08:09:17 +0100 1284138 Nilotinib Active and Safe in Patients With Imatinib-Resistant/Intolerant Chronic-Phase Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=1284137&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F735.aspx 18-month survival rate of 91% among patients with imatinib-resistant/intolerant chronic-phase chronic myeloid leukemia treated with nilotinib (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1284137 Fri, 07 Mar 2008 08:09:17 +0100 1284137 INNO-406 Active and Well Tolerated in Patients With Ph-Positive CML and ALL Who Have Failed Multiple Tyrosine Kinase Inhibitors http://www.medworm.com/index.php?rid=1275374&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F469.aspx INNO-406, novel dual Bcr-Abl/Lyn kinase inhibitor, demonstrates activity in imatinib-resistant/intolerant CML and ALL population (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1275374 Tue, 04 Mar 2008 08:08:02 +0100 1275374 Low Sensitivity BCR-ABL Mutants Identified in Vitro Correspond With Reduced Response to Dasatinib in Patients With Chronic-Phase CML http://www.medworm.com/index.php?rid=1259266&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F319.aspx Sensitivity of BCR-ABL mutants to dasatinib corresponds to hematologic and cytogenetic response rates in patients with chronic-phase CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1259266 Wed, 27 Feb 2008 08:07:44 +0100 1259266 Dasatinib Induces High Response Rates and Is Well Tolerated in Treatment-Naive Patients With Early CP CML http://www.medworm.com/index.php?rid=1232607&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F30.aspx In this study, most patients with treatment-naive, early chronic-phase chronic myeloid leukemia achieved complete cytogenetic response after 18 months of dasatinib therapy (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1232607 Fri, 15 Feb 2008 08:06:26 +0100 1232607 Time to Complete Cytogenetic Response Does Not Predict Outcomes in Chronic-Phase CML Treated With Imatinib http://www.medworm.com/index.php?rid=1213795&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F27.aspx Complete cytogenetic response to imatinib in patients with newly diagnosed chronic-phase CML was associated with excellent outcomes, regardless of when the response was achieved. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1213795 Thu, 07 Feb 2008 20:03:47 +0100 1213795 Response to Imatinib Sustained in 6-Year Follow-up With Continued Safety in Newly Diagnosed Chronic-Phase CML http://www.medworm.com/index.php?rid=1213794&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F25.aspx Results of 6-year follow-up study demonstrate continued safety and efficacy of imatinib therapy in chronic-phase CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1213794 Thu, 07 Feb 2008 20:03:47 +0100 1213794 Responses to Dasatinib in Patients With Imatinib-Resistant/Intolerant Chronic-Phase CML Maintained in 2-Year Follow-up of START-C Trial http://www.medworm.com/index.php?rid=1199268&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F734.aspx Twenty-four month follow-up data show that dasatinib is effective in patients with imatinib-resistant or imatinib-intolerant chronic-phase CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1199268 Mon, 04 Feb 2008 19:59:41 +0100 1199268 Addition of Imatinib Did Not Affect Survival in Patients With Ph-Positive ALL in Preliminary Analysis of UK Study http://www.medworm.com/index.php?rid=1186720&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F8.aspx In the UKALLXII/ECOG 2993 trial, imatinib did not appear to improve overall or event-free survival in patients with Ph-positive ALL when compared with a historic preimatinib cohort from the same study (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1186720 Wed, 30 Jan 2008 08:06:57 +0100 1186720 Dose-Intense Pediatric Regimen May Improve Outcomes in Adults With Newly Diagnosed ALL http://www.medworm.com/index.php?rid=1171696&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F587.aspx A dose-intense pediatric chemotherapy regimen appears feasible and effective in adult ALL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1171696 Thu, 24 Jan 2008 08:28:10 +0100 1171696 Dasatinib Superior to High-Dose Imatinib in Patients With Imatinib-Resistant Chronic-Phase Chronic Myeloid Leukemia After 2-Year Follow-up http://www.medworm.com/index.php?rid=1161593&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCML%2FCapsules%2F736.aspx 2-year follow-up reveals that dasatinib therapy among patients with chronic-phase chronic myeloid leukemia is associated with superior responses and PFS compared with high-dose imatinib (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1161593 Sat, 19 Jan 2008 08:49:55 +0100 1161593 ASCT-Whether From Siblings or Unrelated Donors--Benefits Patients With High-Risk AML in First CR http://www.medworm.com/index.php?rid=1151408&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F169.aspx In patients with high-risk AML in first CR, survival improved following ASCT, regardless of unrelated vs sibling donors (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1151408 Tue, 15 Jan 2008 21:12:51 +0100 1151408 Rituximab-Containing Modified HyperCVAD Regimen Improves DFS in CD20-Positive Younger Adult Patients With ALL http://www.medworm.com/index.php?rid=1133198&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F2824.aspx Rituximab addition to modified hyper-CVAD improves DFS but not OS in younger adult patients with ALL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1133198 Mon, 07 Jan 2008 23:48:38 +0100 1133198 In AML, Idarubicin Induction Produces More CRs Than High-Dose Daunorubicin Whereas IL-2 in Maintenance Therapy Offers No Clear Survival Benefit http://www.medworm.com/index.php?rid=1133197&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F162.aspx In AML induction therapy, idarubicin produces more and earlier CRs than high-dose daunorubicin whereas maintenance IL-2 failed to improve DFS (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1133197 Mon, 07 Jan 2008 23:48:38 +0100 1133197 CD20 Expression Associated With Poor Outcome in Adult Patients With B-Cell Precursor ALL http://www.medworm.com/index.php?rid=1130054&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F2829.aspx In adult B-cell precursor acute ALL, patients with CD20 expression have higher relapse rates than CD20-negative counterparts. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1130054 Sat, 05 Jan 2008 11:35:03 +0100 1130054 Imatinib Added to HyperCVAD Demonstrates Favorable 3-Year DFS and OS in Acute Lymphoblastic Leukemia http://www.medworm.com/index.php?rid=1130053&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F9.aspx HyperCVAD plus imatinib therapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia superior to hyperCVAD alone. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1130053 Sat, 05 Jan 2008 11:35:03 +0100 1130053 Patients With AML Often Do Not Opt for Consolidation Recombinant IL-2, Despite Possible Therapeutic Benefit http://www.medworm.com/index.php?rid=1129122&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F157.aspx Whereas recombinant IL-2 may offer therapeutic benefit in AML in first CR after completion of all planned chemotherapy, many patients often decline to use it or discontinue use early. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1129122 Fri, 04 Jan 2008 12:48:35 +0100 1129122 High-Dose Pediatric Regimens Feasible in Adult ALL http://www.medworm.com/index.php?rid=1125400&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F2822.aspx Dose-intense pediatric chemotherapy improves response and survival rates in adult ALL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1125400 Thu, 03 Jan 2008 00:51:14 +0100 1125400 In AML, Complete Response, Strictly Defined, Predicts Increased Long-term Survival After Cytarabine Induction http://www.medworm.com/index.php?rid=1125399&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FALL%2520AML%2520APL%2FCapsules%2F298.aspx New paradigms of response notwithstanding, survival to 3 years and beyond in patients with AML treated with cytarabine induction is uncommon without standard CR. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1125399 Thu, 03 Jan 2008 00:51:14 +0100 1125399 High Rate of Serious Infections Following Alemtuzumab Consolidation Therapy in Patients With Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=1120125&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F756.aspx Alemtuzumab consolidation therapy following fludarabine induction associated with higher overall risk of serious infection compared with single-agent fludarabine and fludarabine plus rituximab (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1120125 Sat, 29 Dec 2007 00:46:14 +0100 1120125 CLL Cell Count Independent Risk Factor for Progressive Lymphocytosis in Patients With Monoclonal B-Cell Lymphocytosis http://www.medworm.com/index.php?rid=1118606&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F749.aspx In patients with monoclonal B-cell lymphocytosis, the risk of progressive disease correlates with baseline CLL cell count (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1118606 Fri, 28 Dec 2007 00:53:58 +0100 1118606 CD38 Status Predicts Disease Progression for Patients With Monoclonal B-Cell Lymphocytosis http://www.medworm.com/index.php?rid=1118605&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F748.aspx CD38 status identified as strong prognostic marker for the small subset of patients with monoclonal B-cell lymphocytosis who will require treatment within 5 years of diagnosis (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1118605 Fri, 28 Dec 2007 00:53:58 +0100 1118605 Genomic Complexity Identifies Patients With Aggressive Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=1110497&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F489.aspx SNP analysis of genomic complexity identifies patients with aggressive CLL (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1110497 Sat, 22 Dec 2007 00:54:43 +0100 1110497 First-Line Fludarabine vs Chlorambucil in Elderly Patients With CLL: Higher Response Rate but No Survival Advantage http://www.medworm.com/index.php?rid=1107650&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F629.aspx Fludarabine therapy compared with chlorambucil in elderly patients with CLL appears to increase response without offering survival benefit. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1107650 Fri, 21 Dec 2007 00:53:46 +0100 1107650 CFAR Highly Active in Patients With High-Risk CLL http://www.medworm.com/index.php?rid=1107649&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F628.aspx CFAR therapy was highly active and well tolerated in patients with high-risk CLL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1107649 Fri, 21 Dec 2007 00:53:46 +0100 1107649 Alemtuzumab Consolidation Therapy Associated With Severe Infections in Patients With CLL Who Achieve Complete Responses With Induction Therapy: Interim Safety Analysis of CALGB Study 10101 http://www.medworm.com/index.php?rid=1102350&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F755.aspx Alemtuzumab consolidation therapy in patients with CLL achieving a complete response after induction therapy resulted in unacceptable toxicity. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1102350 Wed, 19 Dec 2007 00:55:21 +0100 1102350 Phosphatase Inhibition Studies Reveal Dysregulation of Signaling in CLL Cells http://www.medworm.com/index.php?rid=1102349&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F743.aspx Based on contrasting responses in B-cell receptor signaling following phosphatase inhibition, patients with CLL can be grouped into 2 categories, with possible implications for prognosis and development of targeted therapeutics. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1102349 Wed, 19 Dec 2007 00:55:21 +0100 1102349 In Patients With CLL, Survival Poor When Cytopenia Is Due to Bone Marrow Failure http://www.medworm.com/index.php?rid=1099283&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F746.aspx In patients with CLL who experience cytopenia, survival is variable with autoimmune etiology, but poor with bone marrow failure. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1099283 Tue, 18 Dec 2007 00:48:18 +0100 1099283 CD69 Positivity Predicts Poor Survival in Patients With B-Cell Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=1099282&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FTracks%2FCLL%2FCapsules%2F750.aspx CD69 an independent prognostic factor for patients with B-cell chronic lymphocytic leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1099282 Tue, 18 Dec 2007 00:48:18 +0100 1099282 Staying Focused on a Moving Target: Myelodysplastic Syndrome http://www.medworm.com/index.php?rid=1094961&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FResources%2FCME%2520Options%2FLeukemia%2FModules%2FMyelodysplastic%2520Syndrome.aspx Advances in understanding the molecular mechanisms involved and the increasing number of clinical trials using novel agents and therapeutic regimens have translated into new hope for patients with MDS and leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1094961 Sat, 15 Dec 2007 00:51:41 +0100 1094961 Treating MDS and Leukemia in the Age of Targeted Therapies: Acute Lymphoblastic Leukemia http://www.medworm.com/index.php?rid=1094960&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FResources%2FCME%2520Options%2FLeukemia%2FModules%2FAcute%2520Lymphoblastic%2520Leukemia.aspx Advances in understanding the molecular mechanisms involved and the increasing number of clinical trials using novel agents and therapeutic regimens have translated into new hope for patients with MDS and leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1094960 Sat, 15 Dec 2007 00:51:41 +0100 1094960 Treating MDS and Leukemia in the Age of Targeted Therapies: Staying Focused on a Moving Target: Acute Myeloid Leukemia http://www.medworm.com/index.php?rid=1094959&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FResources%2FCME%2520Options%2FLeukemia%2FModules%2FAcute%2520Myeloid%2520Leukemia.aspx Advances in understanding the molecular mechanisms involved and the increasing number of clinical trials using novel agents and therapeutic regimens have translated into new hope for patients with MDS and leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=1094959 Sat, 15 Dec 2007 00:51:41 +0100 1094959 Imatinib Resistance in the Treatment of Chronic Myeloid Leukemia: Current Management Options and Emerging Therapies http://www.medworm.com/index.php?rid=857388&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FImatinib%2520Resistance.aspx Elias Jabbour, MD; Jorge E. Cortes, MD; and Hagop M. Kantarjian, MD, discuss current and evolving treatments for chronic myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=857388 Tue, 11 Sep 2007 00:21:17 +0100 857388 Clinical Issues and Future Directions in Hematologic Malignancies: Myelodysplastic Syndromes and Acute Leukemias http://www.medworm.com/index.php?rid=546758&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHematology%2520Highlights%2FVirtual%2520Presentations%2FRavandi.aspx Listen to Farhad Ravandi, MD, present the most up-to-date data from the 2006 hematology meeting in Orlando and highlight the clinical implications for improving outcomes in patients with myelodysplastic syndromes and acute leukemias. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=546758 Mon, 16 Apr 2007 18:10:02 +0100 546758 Clinical Issues and Future Directions in Hematologic Malignancies: Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=533982&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FHematology%2520Highlights%2FVirtual%2520Presentations%2FTalpaz.aspx Listen to Moshe Talpaz, MD, present the most up-to-date data from the 2006 annual meeting of the American Society of Hematology and highlight the clinical implications for improving outcomes in patients with chronic myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=533982 Tue, 10 Apr 2007 13:05:02 +0100 533982 Expert Analysis: Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=519685&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FTracks%2FCLL%2FCLL.aspx John C. Byrd, MD, Michael J. Keating, MB BS, amd Susan M. O'Brien, MD, review new CLL data from Atlanta. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=519685 Wed, 04 Apr 2007 07:55:01 +0100 519685 The Development and Diagnosis of Acute Lymphocytic Leukemia http://www.medworm.com/index.php?rid=507606&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%2FModules%2Fcoutre.aspx Steven Coutre, MD, discusses the development of acute lymphocytic leukemia and currently practiced diagnostic techniques and provides a review of treatment, including therapy in Philadelphia chromosomepositive patients. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=507606 Thu, 29 Mar 2007 01:50:02 +0100 507606 Key Mutations Implicated in Dasatinib Resistance Identified http://www.medworm.com/index.php?rid=490629&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F836.aspx%3FTrack%3DCML In a retrospective analysis of phase II data, key Bcr-Abl mutations associated with dasatinib resistance in CML and Ph+ ALL patients were identified. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=490629 Thu, 22 Mar 2007 18:10:02 +0100 490629 Dasatinib 100 mg Once Daily Possibly Optimal Dosing Level in Chronic-Phase CML Patients Who Failed Prior Imatinib Therapy http://www.medworm.com/index.php?rid=475025&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F166.aspx%3FTrack%3DCML In patients with chronic-phase (CP) chronic myeloid leukemia (CML) who failed imatinib, dasatinib 100 mg once daily appears to have the best risk-to-benefit ratio vs other dosing strategies, including 70 mg twice daily. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=475025 Fri, 16 Mar 2007 13:10:01 +0100 475025 Preclinical Results Suggest Dasatinib Plus VX-680 May Prevent CML Disease Resistance http://www.medworm.com/index.php?rid=475024&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F2175.aspx%3FTrack%3DCML VX-680 effectively inhibits kinase activity of BCR-ABL/V299L mutation at low micromolar concentrations. Early combination therapy with dasatinib and VX-680 (MK-0457) may successfully prevent resistance to therapy in CML by eliminating BCR-ABL kinase domain mutations. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=475024 Fri, 16 Mar 2007 13:10:01 +0100 475024 Drug Treatment Superior to Hematopoietic Stem Cell Transplantation in Patients With Chronic-Phase CML http://www.medworm.com/index.php?rid=475023&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F427.aspx%3FTrack%3DCML In a phase II trial, drug treatment was associated with significantly higher overall survival compared with standard hematopoietic stem cell transplantation for patients with chronic-phase CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=475023 Fri, 16 Mar 2007 13:10:01 +0100 475023 Management of a 39-Year-Old Male With Intermediate-Risk, Chronic-Phase CML http://www.medworm.com/index.php?rid=461428&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCML%2520Cases%2FInteractive%2520Case%2520Challenges%2FCase%25203.aspx Test your ability to manage newly diagnosed chronic-phase CML in a younger patient classified as high risk according to the Sokal scoring system. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=461428 Sat, 10 Mar 2007 08:10:02 +0100 461428 A 45-Year-Old Woman With CML Who Is Intolerant of Imatinib http://www.medworm.com/index.php?rid=461427&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCML%2520Cases%2FInteractive%2520Case%2520Challenges%2FCase%25202.aspx Test your ability to manage a previously healthy 45-year-old female who experiences malaise, fatigue, and weight loss and is subsequently diagnosed with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in chronic phase. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=461427 Sat, 10 Mar 2007 08:10:02 +0100 461427 Nilotinib Active in CML Patients After Failure of 2 Previous Tyrosine Kinase Inhibitor-Based Therapies http://www.medworm.com/index.php?rid=461426&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F2170.aspx%3FTrack%3DCML According to the results of a phase II, open-label, multicenter study, patients with CML who have failed treatment with both imatinib and dasatinib may achieve hematologic and/or cytogenetic responses when treated with nilotinib. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=461426 Sat, 10 Mar 2007 08:10:02 +0100 461426 Management of a 50-Year-Old Female With High-Risk CML http://www.medworm.com/index.php?rid=461425&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCML%2520Cases%2FInteractive%2520Case%2520Challenges%2FCase%25201.aspx Test your ability to manage a patient who has chronic myeloid leukemia with high-risk features. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=461425 Sat, 10 Mar 2007 08:10:02 +0100 461425 Acute Leukemias/Myelodysplastic Disorders http://www.medworm.com/index.php?rid=447615&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FTracks%2FAcute%2FAcute.aspx Hagop M. Kantarjian, MD, Alan F. List, MD, and Martin S. Tallman, MD, review new data from the meeting in Orlando. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=447615 Sun, 04 Mar 2007 03:10:02 +0100 447615 High Rate of Early Response With Nilotinib in Newly Diagnosed Chronic-Phase CML Patients http://www.medworm.com/index.php?rid=447614&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F2172.aspx%3FTrack%3DCML Findings from a poster presentation at the 2006 American Society of Hematology conference indicated that frontline nilotinib is safe and may be associated with high rates of early complete cytogenetic response in patients with newly diagnosed Ph+ chronic-phase CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=447614 Sun, 04 Mar 2007 03:10:02 +0100 447614 Congestive Heart Failure Incidence Low for Imatinib-Treated Patients With Leukemia http://www.medworm.com/index.php?rid=447613&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F2146.aspx%3FTrack%3DCML Data from a multistudy retrospective analysis presented at the 2006 American Society of Hematology meeting indicates that the incidence of CHF is uncommon in leukemia patients treated with imatinib. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=447613 Sun, 04 Mar 2007 03:10:02 +0100 447613 Chronic Myeloid Leukemia http://www.medworm.com/index.php?rid=447612&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FTracks%2FCML%2FCML.aspx Brian Druker, MD, Charles L. Sawyers, MD, and Moshe Talpaz, MD, discuss treatment implications of the data presented in December. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=447612 Sun, 04 Mar 2007 03:10:02 +0100 447612 Individualized Strategies for the Management of Acute Lymphocytic Leukemia: Implications for Therapy http://www.medworm.com/index.php?rid=447611&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%2FModules%2Fthomas.aspx Join Clinical Care Options expert faculty Deborah A. Thomas, MD, and Susan M. OBrien, MD, as they investigate the role of targeted therapies in the treatment of ALL, including a discussion of individualized treatment according to patient and cytogenetic characteristics. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=447611 Sun, 04 Mar 2007 03:10:02 +0100 447611 FC Induction Followed by Alemtuzumab Consolidation Active, Tolerable in Elderly Treatment-Naive Patients With CLL http://www.medworm.com/index.php?rid=432001&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F2831.aspx%3FTrack%3DCLL In a prospective phase II study, alemtuzumab consolidation therapy following oral induction therapy with fludarabine and cyclophosphamide was associated with a high response rate, and the majority of patients achieved undetectable minimal residual disease. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=432001 Fri, 23 Feb 2007 08:00:01 +0100 432001 Newly Described Biologic Marker-Based Risk Groups Associated With Response and Survival in Patients With Chronic Lymphocytic Leukemia http://www.medworm.com/index.php?rid=432000&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F299.aspx%3FTrack%3DCLL Good-, standard-, and poor-risk groups have been identified on the basis of biologic markers for patients with chronic lymphocytic leukemia (CLL) treated with fludarabine plus cyclophosphamide, single-agent fludarabine, or chlorambucil. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=432000 Fri, 23 Feb 2007 08:00:01 +0100 432000 MK-0457, a Novel Aurora Kinase Inhibitor, Safe and Effective for Treatment of CML Patients With T315I Mutation http://www.medworm.com/index.php?rid=431999&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F163.aspx%3FTrack%3DCML The aurora kinase inhibitor MK-0457 was shown to be safe and effective and correlated with major response in a phase I trial of refractory CML patients. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=431999 Fri, 23 Feb 2007 08:00:01 +0100 431999 Nilotinib Clinically Effective and Safe in Chronic-Phase CML After Failure of Imatinib Therapy http://www.medworm.com/index.php?rid=431998&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F165.aspx%3FTrack%3DCML In a phase II study, complete cytogenetic responses to nilotinib were seen in about one third of patients with chronic-phase (CP) CML who had previously failed imatinib therapy. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=431998 Fri, 23 Feb 2007 08:00:01 +0100 431998 Dasatinib Responses Durable in Chronic-Phase CML Patients Who Failed Prior Imatinib Treatment http://www.medworm.com/index.php?rid=431997&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F164.aspx%3FTrack%3DCML With longer-term follow-up, results of the START-C study now show that responses to dasatinib are durable in patients with chronic-phase CML who failed prior imatinib therapy due to resistance or intolerance. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=431997 Fri, 23 Feb 2007 08:00:01 +0100 431997 Clonal Evolution in Patients With CLL Associated With Poor Clinical Outcomes http://www.medworm.com/index.php?rid=418966&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F296.aspx%3FTrack%3DCLL Clonal evolution was associated with disease progression, need for therapy, and death in this retrospective analysis. Notably, clonal evolution in this study was observed only among patients with unmutated VH status. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=418966 Sat, 17 Feb 2007 02:40:02 +0100 418966 Alemtuzumab Superior to Chlorambucil as First-Line Treatment for Patients With B-Cell CLL http://www.medworm.com/index.php?rid=418965&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F301.aspx%3FTrack%3DCLL In this phase III study, alemtuzumab was more effective than chlorambucil as first-line treatment in patients with progressive B-cell chronic lymphocytic leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=418965 Sat, 17 Feb 2007 02:40:02 +0100 418965 Alemtuzumab Superior to Chlorambucil in B-Cell CLL Patients With High-Risk Cytogenetic Subtypes http://www.medworm.com/index.php?rid=408019&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F2092.aspx%3FTrack%3DCLL Cytogenetic subanalysis of the CAM307 trial confirms that the benefit of alemtuzumab over chlorambucil in patients with B-cell CLL may be particularly pronounced in patients with abnormalities at specific high-risk loci. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=408019 Sat, 10 Feb 2007 22:30:01 +0100 408019 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab a Potent Regimen in Treatment-Experienced CLL Patients http://www.medworm.com/index.php?rid=408018&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F31.aspx%3FTrack%3DCLL Cyclophosphamide, fludarabine, alemtuzumab, and rituximab is a potent and safe regimen in heavily treatment-experienced individuals with CLL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=408018 Sat, 10 Feb 2007 22:30:01 +0100 408018 Lumiliximab Added to Fludarabine, Cyclophosphamide, and Rituximab is Safe and Effective in Relapsed CLL http://www.medworm.com/index.php?rid=408017&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F32.aspx%3FTrack%3DCLL The anti-CD23 monoclonal antibody lumiliximab in combination with FCR was safe and effective in patients with relapsed CLL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=408017 Sat, 10 Feb 2007 22:30:01 +0100 408017 Pentostatin, Cyclophosphamide, and Rituximab Promising for Treatment-Naive Individuals With B-Cell CLL http://www.medworm.com/index.php?rid=392627&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fclinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202006%2FCapsules%2F35.aspx%3FTrack%3DCLL In a nonrandomized trial, investigators reported robust activity and low toxicity for a combination chemoimmunotherapy regimen including PCR in treatment-naive patients with B-cell CLL, irrespective of most high-risk features (except 17p deletion). (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=392627 Fri, 02 Feb 2007 22:40:02 +0100 392627